Literature DB >> 22944376

Perioperative cimetidine administration improves systematic immune response and tumor infiltrating lymphocytes in patients with colorectal cancer.

Boyou Li1, Feilin Cao, Qinlu Zhu, Boli Li, Meifu Gan, Dongguo Wang.   

Abstract

BACKGROUND/AIMS: Cimetidine has been shown to play an important role in the treatment of cancer and the regulation of the immune system. Therefore, we aimed to observe the effects of cimetidine on the systematic immune response in the perioperative period.
METHODOLOGY: Sixty patients with colorectal cancer were enrolled from Jan 2005 to Dec 2005 from Taizhou Hospital. The patients were administrated with cimetidine (0.8 g.d-1 or 1.2 g.d-1) or saline from the day of admission to the 10th POD. Venous blood sample was collected and the T-, B- and NK-lymphocyte subsets were determined by flow cytometry. The specimens were subjected to tumor-infiltrating lymphocytes (TILs) response examination.
RESULTS: The levels of CD3 and CD4 T-lymphocytes were increased significantly in both low and high dose cimetidine groups 10 days after operation. The number of CD19 B cells was also elevated by cimetidine. However, no significant changes were observed in the CD8, CD4/CD8 value. TIL responses in the cimetidine groups were also enhanced significantly.
CONCLUSIONS: Cimetidine can alleviate systematic immunosuppression and improve the local immune function of the colorectal cancer patients in the perioperative period.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22944376     DOI: 10.5754/hge12573

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

Review 1.  The effects of selected drugs and dietary compounds on proliferation and apoptosis in colorectal carcinoma.

Authors:  Miroslaw Kiedrowski; Andrzej Mroz
Journal:  Contemp Oncol (Pozn)       Date:  2014-08-20

Review 2.  Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

Authors:  María de la Paz Sarasola; Mónica A Táquez Delgado; Melisa B Nicoud; Vanina A Medina
Journal:  Pharmacol Res Perspect       Date:  2021-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.